Stock Ratings / Health Care / UNCY / earnings

OKUR (46) IMUX (38) ORGO (50) NERV (38) ⌘ Pro Terminal →

Unicycive Therapeutics Inc. (UNCY) Next Earnings Date & Expected ±12.5% Move

$3.74 -1.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.72

Unicycive Therapeutics Inc. (UNCY) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $106.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UNCY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UNCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Unicycive Therapeutics Inc. (NASDAQ: UNCY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.74 (-1.84% 1D, market cap $106.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, UNCY ranks #414 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UNCY compare to OKUR and IMUX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UNCY carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OKUR (OnKure Therapeutics Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M) and IMUX (Immunic Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $106.4M). Among the 5-stock peer group, UNCY leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UNCY?

▼

Per UNCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766140), Unicycive Therapeutics Inc. generated $0 in revenue, -$26.6M in net income, and -$31.3M in free cash flow against $49.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.72 (-0.52%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UNCY)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY UNCY SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 40.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$4.11-18.2% Next Q

Q2 (-2Q)

Grade C-$3.36+15.8% Next Q

Q3 (-1Q)

Grade D$3.89-3.9% Next Q

Current

Grade D$3.74-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a UNCY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While UNCY currently carries a cautious 45/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.54) and Max Pain ($3.93) forces dealer call-delta covering toward $9.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UNCY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UNCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.47 Expected Swing

MODEL EARNINGS SETUP GAUGE

UNCY Quantitative Pre-Earnings Setup: 45/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (45/100)Model Risk Weight (55/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$26.6M	-$31.3M	52%
FY 2024	2024-12-31	$0	-$36.7M	-$28.6M	52%
FY 2023	2023-12-31	$675.0K	-$30.5M	-$18.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring UNCY)

✓Walkthrough of UNCY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UNCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.17%▼ DESCENDING CHANNEL

2026-10-30O $3.77H $3.93L $3.62C $3.74VOL 978.1K

RES: $5.37SUP: $3.11SMA50: $4.54SMA200: $6.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UNCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UNCY Butterfly Map → + Track UNCY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on UNCY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UNCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UNCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UNCY)

Health Care Rank #414 of 1016 ⚔️ OKUR vs UNCY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UNCY vs. OKUR, IMUX, ORGO, NERV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Unicycive Therapeutics Inc. (UNCY) ranks #414 by composite RQD confidence (45/100, grade D) and #653 by equity capitalization ($106.1M). Within this direct 5-issuer industry benchmark cohort, UNCY leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with UNCY at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UNCY ACTIVE Unicycive Therapeutics Inc.	D	45/100	—	—	-35.0%	-1.84%	$106.1M	Benchmark Subject
OKUR OnKure Therapeutics Inc. (Class A)	D	46/100	—	—	-35.0%	0.00%	$106.1M	/okur-vs-uncy →
IMUX Immunic Inc.	D-	38/100	—	—	-35.0%	-3.66%	$106.4M	/imux-vs-uncy →
ORGO Organogenesis Holdings Inc. (Class A)	D	50/100	—	—	17.1%	-6.20%	$105.4M	/orgo-vs-uncy →
NERV Minerva Neurosciences Inc	D-	38/100	—	—	-35.0%	+3.57%	$107.0M	/nerv-vs-uncy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001766140

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Unicycive Therapeutics Inc. (UNCY) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$26.6M, operating cash flow of -$31.3M, and free cash flow of -$31.3M (-9.4% YoY). On the balance sheet, UNCY closed FY2025 with $49.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.6M	-$31.3M	-$31.3M	$49.1M	—
FY2024 (FY)	2024-12-31	$0	-$36.7M	-$28.6M	-$28.6M	$31.7M	—
FY2023 (FY)	2023-12-31	$675.0K	-$30.5M	-$18.3M	-$18.3M	—	—

3. UNCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UNCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does UNCY compare to OKUR and IMUX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for UNCY?

Where is UNCY trading relative to its 50-day, 200-day, and 52-week technical levels?

UNCY last traded at $3.74 (-1.84% on volume of 1,300,302 shares), positioning the stock -17.62% below its 50-day simple moving average ($4.54) and -38.69% below its 200-day simple moving average ($6.10). Across its 52-week range of $3.35 to $8.74, UNCY sits at the 7.2% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.27 to $4.21).

UNCY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is UNCY's next earnings date?

Based on SEC filing cadence, Unicycive Therapeutics Inc. (UNCY)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is UNCY stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for UNCY, spanning a range between $3.27 and $4.21.

Direct Sub-Reports: UNCY RQD Cockpit UNCY 12M Forecast UNCY Earnings & Move UNCY Dividends & DRIP UNCY Insiders & 13F UNCY Whale Options UNCY Profit Sankey UNCY News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

UNCY — Unicycive Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:54Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD Score is 45 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars are:

Fundamental Cash Engine: 4 / 20. The rating cites ROIC of -35% and an FCF yield of 0% (per the Roarable RQD rating and market data). This is the weakest pillar and reflects the absence of positive cash generation in the reported periods.
Whale 13F Flow: 11 / 20. Scored on institutional accumulation and options positioning. The holders section contains no 13F detail, so the underlying positioning cannot be verified from the provided data.
Insider Conviction: 5 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. No insider transaction records are provided in the source data, so the low score cannot be traced to specific trades here.
Macro Regime Fit: 15 / 20. Reflects a beta of 1.0 and sector sensitivity (per the Roarable RQD rating and market data).
Forensic Balance Sheet: 10 / 20. Reflects Altman Z 2.5, Piotroski F 2/9, and Debt/Equity 0.5 (per the Roarable RQD rating).

For a prospective investor, the practical implication is that the score is driven by the absence of earnings and cash generation rather than by leverage. The balance sheet pillar is middling rather than weak, and the macro pillar is moderate. Upside would depend on operating results improving faster than the current cash-burn profile suggests, which the source data does not evidence. The valuation tradeoff is that a $106.1M market capitalization is being carried without positive earnings or free cash flow, so the price rests on future outcomes not captured in these sources. This is an analytical reading of the rating, not personalized advice.

Business

Unicycive Therapeutics Inc. (UNCY) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.1B. The source data does not describe the company's products, customers, or revenue model. Revenue is reported as $0.0M in FY 2025 and FY 2024 (per the SEC financials), indicating no meaningful commercial revenue in those periods.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-29.5M	$-26.6M	N/A	$-31.3M	$29.2M	N/A
FY 2024	$0.0M	$-32.1M	$-36.7M	N/A	$-28.6M	$26.1M	N/A
FY 2023	$0.7M	$-20.8M	$-30.5M	N/A	$-18.3M	N/A	N/A

Profitability is negative across all three reported periods, with operating losses, net losses, and negative free cash flow (per the SEC financials). Gross, operating, and net margins are each listed as 0% (per market data), and ROIC is -35%. The Roarable RQD rating records an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5. Cash was $29.2M at FY 2025 and $26.1M at FY 2024 against continued negative free cash flow. Debt is listed as N/A in the reported periods.

Recent Catalysts & News Wire Analysis

The news wire contains six items, all tagged YELLOW with the impact label "MARKET WIRE":

A Yahoo Finance report describing a 21.4% decline over four weeks and a possible trend reversal.
A Morningstar-syndicated notice reminding investors of a securities class action deadline on November 2, 2026.
A Zacks Investment Research piece asking whether to buy the stock.
A Moomoo options-chain page.
A Stocktwits report describing a 45% single-day decline and asking why the FDA rejected the kidney disease NDA a second time.
A National Law Review item from Kaplan Fox encouraging shareholders in the company.

Risk watch items from the feed are the reported second FDA rejection of the kidney disease NDA (per the Stocktwits headline) and the active securities class action deadline (per the Morningstar item). The feed contains no positive proprietary signals. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

Open Questions

What products or drug candidates does the company develop, and what is the status of the kidney disease NDA following the reported second FDA rejection?
What is the cash runway implied by $29.2M in cash against FY 2025 free cash flow of $-31.3M, and how will the company fund continued losses?
What are the allegations and scope of the securities class action referenced in the news feed?
What is the company's debt position, given that debt is listed as N/A while Debt/Equity is cited as 0.5?
Why are EPS, P/E, and EV/EBITDA unavailable, and what share count underlies the $106.1M market capitalization?

UNCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Unicycive Therapeutics Inc. (UNCY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UNCY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 5h ago

Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Yahoo Finance report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Morningstar • 8h ago

UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026

Morningstar report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Zacks Investment Research • 11h ago

Should I buy Unicycive Therapeutics (UNCY)

Zacks Investment Research report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 14h ago

Unicycive Therapeutics(UNCY) Stock Options Chain | Quotes & News

Moomoo report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 17h ago

UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?

Stocktwits report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The National Law Review • 20h ago

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY)

The National Law Review report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 23h ago

Unicycive Therapeutics (Nasdaq:UNCY) - Stock Analysis

Simply Wall St report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Unicycive Therapeutics, Inc. Estimates – NASDAQ:UNCY

TradingView report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UNCY Bull vs. Bear Conversation Board — What's Your Call at $3.74?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UNCY 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.29 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is UNCY (D • RQD 45/100) a Buy at $3.74?

Welcome to the UNCY (Unicycive Therapeutics Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.10 (-17.1%)

Spot @ $3.74

Pump the brakes on UNCY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on UNCY, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Unicycive Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.49 (+20.1%)

Spot @ $3.74

UNCY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on UNCY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.74 (52-wk range $3.35 - $8.74), any beat on forward guidance forces shorts and underweight funds to chase.